68
Participants
Start Date
February 15, 2018
Primary Completion Date
December 28, 2023
Study Completion Date
December 25, 2025
VAY736
VAY736
Placebo
Placebo control with conversion to active VAY736
Novartis Investigative Site, Bern
Novartis Investigative Site, Ghent
Novartis Investigative Site, Vinohrady
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Hanover
Novartis Investigative Site, Aachen
Novartis Investigative Site, Mainz
St. Lukes Advanced Liver Therapies, Houston
Southern California Research Center, Coronado
Inland Empire Liver Foundation, Rialto
University of California Davis Medical Center, Sacramento
Novartis Investigative Site, Würzburg
Novartis Investigative Site, CABA
Novartis Investigative Site, CABA
Novartis Investigative Site, Edmonton
Novartis Investigative Site, Toronto
Novartis Investigative Site, Montreal
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Takamatsu
Novartis Investigative Site, Itabashi Ku
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Birmingham
Novartis Investigative Site, London
Novartis Investigative Site, Newcastle upon Tyne
Novartis Investigative Site, Nottingham
Novartis Investigative Site, Oxford
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY